Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.

Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, Daly OA, Nguyen J, Ignacio CC, Spina CA, Richman DD, Wong JK.

J Infect Dis. 2005 May 1;191(9):1410-8. Epub 2005 Mar 29.

PMID:
15809898
2.

IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.

Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, Acheampong EA, Fisher J, Sierra M, Thomson MM, Najera R, Frank I, Kulkosky J, Pomerantz RJ, Nunnari G.

J Clin Invest. 2005 Jan;115(1):128-37.

3.

Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors.

Ylisastigui L, Coull JJ, Rucker VC, Melander C, Bosch RJ, Brodie SJ, Corey L, Sodora DL, Dervan PB, Margolis DM.

J Infect Dis. 2004 Oct 15;190(8):1429-37. Epub 2004 Sep 15.

PMID:
15378435
4.
5.

Interleukin-7 induces HIV type 1 outgrowth from peripheral resting CD4+ T cells.

Lehrman G, Ylisastigui L, Bosch RJ, Margolis DM.

J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1103-4. No abstract available.

PMID:
15247565
6.

Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations.

Clotet B, Raffi F, Cooper D, Delfraissy JF, Lazzarin A, Moyle G, Rockstroh J, Soriano V, Schapiro J.

AIDS. 2004 May 21;18(8):1137-46. Review.

PMID:
15166529
7.

Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression.

Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM.

AIDS. 2004 May 21;18(8):1101-8.

PMID:
15166525
8.

Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid.

Antoniou T, Gough K, Yoong D, Arbess G.

Clin Infect Dis. 2004 Mar 1;38(5):e38-40. Epub 2004 Feb 11.

PMID:
14986271
9.

Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication.

Ramratnam B, Ribeiro R, He T, Chung C, Simon V, Vanderhoeven J, Hurley A, Zhang L, Perelson AS, Ho DD, Markowitz M.

J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):33-7.

PMID:
14707789
10.

New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma.

Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, Dewar RL, Planta A, Liu S, Metcalf JA, Mellors JW, Coffin JM.

J Clin Microbiol. 2003 Oct;41(10):4531-6.

11.
12.

Molecular characterization, reactivation, and depletion of latent HIV.

Brooks DG, Hamer DH, Arlen PA, Gao L, Bristol G, Kitchen CM, Berger EA, Zack JA.

Immunity. 2003 Sep;19(3):413-23.

13.

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF.

Nat Med. 2003 Jun;9(6):727-8. Epub 2003 May 18.

PMID:
12754504
14.

Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence.

Strain MC, Günthard HF, Havlir DV, Ignacio CC, Smith DM, Leigh-Brown AJ, Macaranas TR, Lam RY, Daly OA, Fischer M, Opravil M, Levine H, Bacheler L, Spina CA, Richman DD, Wong JK.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4819-24. Epub 2003 Apr 8.

15.

Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1.

Pomerantz RJ.

HIV Clin Trials. 2003 Mar-Apr;4(2):137-43. Review.

PMID:
12671782
16.
17.

Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides.

Coull JJ, He G, Melander C, Rucker VC, Dervan PB, Margolis DM.

J Virol. 2002 Dec;76(23):12349-54.

18.

Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.

Kulkosky J, Nunnari G, Otero M, Calarota S, Dornadula G, Zhang H, Malin A, Sullivan J, Xu Y, DeSimone J, Babinchak T, Stern J, Cavert W, Haase A, Pomerantz RJ.

J Infect Dis. 2002 Nov 15;186(10):1403-11. Epub 2002 Oct 29.

PMID:
12404155
19.

Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).

Stellbrink HJ, van Lunzen J, Westby M, O'Sullivan E, Schneider C, Adam A, Weitner L, Kuhlmann B, Hoffmann C, Fenske S, Aries PS, Degen O, Eggers C, Petersen H, Haag F, Horst HA, Dalhoff K, Möcklinghoff C, Cammack N, Tenner-Racz K, Racz P.

AIDS. 2002 Jul 26;16(11):1479-87. Erratum in: AIDS 2002 Oct 18;16(15):2103.

PMID:
12131185

Supplemental Content

Support Center